Overview

PARP Inhibitors Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027.

Increasing prevalence of cancer, rising acceptance of PARP inhibitors drugs, increased geriatric population and scientific advancements in the healthcare sector across the world are some of the kay factors contributing to the growth of the market. Moreover, the key market players are introducing novel techniques for developing advanced cancer treatments which shall propel the PARP inhibitors market growth. On the other hand, strict governmental regulations and frequent product recalls are predicted to impede the market growth substantially in the upcoming years.
For many years, cancer has been the leading cause of death across the world. As per the WHO, cancer is the reason for over 8 million deaths each year, with over 65% new cancer cases are anticipated to be registered over the next two decades. Rising population afflicted with cancer shall prove to be a key factor in the augmentation of the market. As per the data provided by the CDC, 2014, the number of cancer patients reached over 20 million in the United States and it is estimated that this number shall reach over 25 million by 2024 end. Additionally, the rising geriatric population getting diagnosed with cancer shall propel the growth of the market. As per the Administration for Community Living, the number of people over the age of 65 in the United States were over 46 million in 2014.

PARP Inhibitors Market

Market Segmentation:

By Drug Type
•   Lynaprza
•   Niraparib
•   Rucaparib
•   Talazoparib
•   Veliparib
•   Others
By Indication
•   Ovarian Cancer
•   Breast Cancer
•   Prostate Cancer
•   Pancreatic Cancer
•   Lung Cancer
•   Others
By Distribution channel
•   Hospital Pharmacies
•   Retail Pharmacies
•   Online Pharmacies
•   Others
By Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

The market is classified into drug type, indication, distribution channel and region. The drug type segment is diversified into lynaprza, niraparib, rucaparib, talazoparib, veliparib and others. The indication segment is fragmented into ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, lung cancer and others. The distribution channel segment is bifurcated into hospital pharmacies, retail pharmacies, online pharmacies and others.

Regional Analysis:

The North America region is expected to lead the market during the forecast period owing to the rising geriatric population, increased prevalence of cancer owing to unhealthy lifestyle and dietary choices and a strong presence of key market players in the region.

Competitive Landscape:

Some of the major market players associated are AstraZeneca, Tesaro, AbbVie Inc., Medivation, Clovis Oncology. AstraZeneca is primarily engaged in manufacturing, discovery, commercialization, distribution of biopharma products. It provides different services in therapeutics for metabolic and cardiovascular diseases, respiratory, oncological, autoimmunity and inflammation.

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global PARP inhibitors market by drug type, by indication, by distribution channel and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com